Recently, miR-363 has been reported to negatively regulate myeloid cell leukemia-1 (Mcl-2), an anti-apoptotic protein from the Bcl-2 family, and sensitize breast cancer cells to cisplatin [67]. Here, BCL2 is linked to breast cancer.